MedTrace Logo

Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer

NCT01004419 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-10-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of vandetanib and fulvestrant; to find the maximum tolerated dose of these two drugs; and to evaluate response rate and assess toxicity of this combination.

Conditions

  • Carcinoma, Non Small Cell Lung

Interventions

DRUG

ZD6474 (vandetanib)

vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days

DRUG

Faslodex (Fulvestrant)

Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University of Pittsburgh

    collaborator OTHER

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Tien Hoang, M.D. · University of Wisconsin, Madison

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-11-30
Completion
2011-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01004419 on ClinicalTrials.gov